Medtronic PLC will pay Edwards Lifesciences Corp. $750 million, plus ongoing royalty payments of at least $40 million a year through April 2022, to settle the long-running legal dispute over transcatheter aortic valve replacement (TAVR) patents.
As part of the cross-license settlement, Medtronic and Edwards have agreed to not sue each other anywhere in the world over patents related to aortic or other transcatheter heart valves...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?